Welcome to our dedicated page for Adagene news (Ticker: ADAG), a resource for investors and traders seeking the latest updates and insights on Adagene stock.
Adagene Inc (NASDAQ: ADAG) is a clinical-stage biopharmaceutical pioneer leveraging AI and proprietary platforms like SAFEbody® to develop precision antibody therapies for cancer. This page provides investors and industry professionals with timely updates on material developments, including clinical trial progress, strategic collaborations, and regulatory milestones.
Access authoritative updates on ADAG’s antibody discovery pipeline, including its lead candidate ADG126 targeting colorectal cancer. The repository consolidates press releases, financial disclosures, and research breakthroughs related to the company’s Dynamic Precision Library technology and therapeutic innovations.
Key content categories include clinical trial results, partnership announcements with global biopharma leaders, and updates on novel platforms addressing on-target off-tumor toxicity challenges. All materials adhere to factual reporting standards, providing stakeholders with reliable data for informed analysis.
Bookmark this page for streamlined access to Adagene’s latest developments in computational antibody engineering. Check regularly for updates on how ADAG’s masked antibody therapies are redefining safety and efficacy standards in oncology.
Adagene (Nasdaq: ADAG) presented preclinical data at the 63rd American Society of Hematology Annual Meeting, highlighting two promising programs: ADG153, an anti-CD47 monoclonal antibody, and ADG152, a CD20xCD3 bispecific T-cell engager. ADG153 demonstrated reduced hematologic toxicities and an 8-fold prolonged half-life, while ADG152 showcased enhanced therapeutic index with minimized cytokine release. These findings support advancing both candidates into clinical development, showcasing Adagene's commitment to innovative cancer immunotherapies and the strength of its AI-driven antibody platform.
Adagene Inc. has presented promising clinical data on its anti-CTLA-4 monoclonal antibody ADG116 and anti-CD137 agonist ADG106 at the ESMO-IO Congress 2021. ADG116 showed a strong safety profile and early efficacy signals in patients with advanced solid tumors, with a notable 22% tumor reduction in a pancreatic cancer patient. Additionally, ADG106 demonstrated significant synergy with toripalimab, enhancing immune activation. These findings reinforce Adagene's commitment to developing innovative antibody-based immunotherapies and advancing its clinical pipeline.
Adagene presented promising clinical data for its monoclonal antibodies, ADG116 and ADG106, at the ESMO-IO Congress 2021. The ongoing trial of ADG116 indicated a strong safety profile with early efficacy signals in treatment-resistant tumors. Key findings included a 22% reduction in tumor size for a pancreatic cancer patient and evidence of immune activation. ADG106 showed enhanced immune response when combined with toripalimab. The trials aim to advance these therapies targeting advanced solid tumors, reinforcing Adagene's commitment to innovative cancer treatments.
Adagene has received FDA clearance for the IND application to initiate the Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody, ADG116, in combination with pembrolizumab. The global study (ADG116-P001) will target advanced metastatic solid tumors and will commence in early 2022 across multiple sites in the U.S. and Asia Pacific. This trial aims to evaluate safety, tolerability, and preliminary efficacy. Additionally, the ongoing ADG116-1003 trial will explore ADG116 in combinations with other therapies.
Adagene Inc. (Nasdaq: ADAG) announced two poster presentations at the ESMO-IO Congress 2021 showcasing clinical data for its anti-CD137 agonist, ADG106, and anti-CTLA-4 monoclonal antibody, ADG116. The data highlight the potential of the NEObody™ technology in improving T-cell activation and safety profiles in cancer immunotherapy. Key presentations include biomarker kinetics for ADG106 and a dose-finding study for ADG116. The conference takes place from December 8-11, 2021, with details available after December 2.
Adagene Inc. (Nasdaq: ADAG) announced its participation in several investor and industry conferences throughout November 2021. Key events include one-on-one meetings during the Goldman Sachs Asia Pacific Healthcare Forum from November 15-17, its presentation at the 8th Annual BioCentury-BayHelix China Healthcare Summit from November 16-19, and on-demand viewing of its presentation at the Jefferies London Healthcare Conference starting November 18. Additionally, an on-demand presentation for the Piper Sandler 33rd Annual Virtual Healthcare Conference will be available from November 22.
Adagene Inc. (Nasdaq: ADAG) announced the presentation of promising preclinical data for its antibody candidates ADG153 (anti-CD47 SAFEbody) and ADG152 (CD20xCD3 POWERbody). These candidates aim to tackle development challenges in immuno-oncology. Notable performance includes ADG153's strong anti-tumor activity with minimal liabilities and ADG152 showing an enhanced therapeutic index. The results will be presented at the ASH Annual Meeting in December 2021, with implications for potential Investigational New Drug applications.
Adagene has initiated a phase 1b/2 clinical trial of ADG106, an anti-CD137 agonist antibody, in combination with Nivolumab, targeting advanced non-small cell lung cancer (NSCLC). Conducted at the National University Cancer Institute, Singapore, this trial aims to evaluate safety, tolerability, and anti-tumor efficacy in up to 53 patients who have failed prior treatments. The promising pre-clinical results suggest potential for ADG106 to enhance T-cell activity and address resistance to current therapies.
Adagene Inc. (Nasdaq: ADAG) announced on October 21, 2021, that CEO Peter Luo, Ph.D., will provide a corporate update at the Jefferies Virtual China Biotech Summit on October 26, 2021, at 3:00 p.m. Eastern. The online presentation will offer investors insights into Adagene’s advancements in antibody-based immunotherapies. A live webcast will be available on the company’s website, with a replay accessible for at least 30 days. Adagene leverages AI and computational biology to develop novel immunotherapy solutions using its proprietary Dynamic Precision Library platform.
Adagene Inc. (Nasdaq: ADAG), a clinical-stage biopharmaceutical company, announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference scheduled for September 9-15, 2021. Peter Luo, Co-founder and CEO, will present on September 10, 2021, at 2:00 p.m. Eastern. A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days. Adagene focuses on antibody-based cancer immunotherapies, leveraging its proprietary Dynamic Precision Library platform to meet unmet patient needs.
FAQ
What is the current stock price of Adagene (ADAG)?
What is the market cap of Adagene (ADAG)?
